Cerebral glucose metabolism, cerebrospinal fluid-β-amyloid1-42 (CSF-Aβ42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients

Neuroscience Letters

Volumn 338, Issue 2, 2003, Pages 159-163

  Stefanova, E ^a   Blennow, K ^b   Almkvist, O ^a   Hellstrom Lindahl E ^a   Nordberg, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Cerebrospinal fluid tau (CSF tau); Cerebrospinal fluid amyloid1 42 (CSF A 42); Cholinesterase inhibitors; Glucose metabolism; Positron emission tomography (PET)

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; GLUCOSE; RIVASTIGMINE; TACRINE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; BRAIN; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; GLUCOSE METABOLISM; HUMAN; MALE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0344238739     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)01384-8     Document Type: Review

References (21)

1. (1-42) in Alzheimer's disease and stability during the course of disease. Arch. Neurol. 56:1999;673-680.
2. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., Raiha I., Sourander L., Winblad B., Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry. 64:1998;298-305.
3. Blennow K., Wallin A., Agren H., Spenger C., Sieggfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26:1995;231-245.
4. Blomberg M., Jensen M., Basun H., Lannfelt L., Wahlund L.O. Increasing cerebrospinal levels fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ε4 during 14 months follow-up. Neurosci. Lett. 214:1996;163-166.
5. Corder E.H., Jelic V., Basun H., Lannfelt L., Valind S., Winblad B., Nordberg A. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch. Neurol. 54:1997;273-277.
6. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
7. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., Seubert P. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55:1998;937-945.
8. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 14:(Suppl. 1):2000;S3-S10.
9. Hellström-Lindahl E., Moore H., Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J. Neurochem. 74:(2):2000;777-784.
10. Herholz K., Nordberg A., Salmon E., Perani D., Kessler J., Mielke R., Halber M., Jelic V., Almkvist O., Collette F., Alberoni M., Kennedy A., Hasselbalch S., Fazio F., Heiss W.-D. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 10:1999;494-504.
11. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T., Watanabe M., Tomidokoro Y., Shizuka M., Mizushima K., Nakamura T., Igeta Y., Ikeda Y., Amari M., Kawarabayashi T., Ishiguro K., Harigaya Y., Wakabayashi K., Okamoto K., Hirai S., Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, Aβ 1-40 and Aβ 18-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 44:1998;17-26.
12. Kanai M., Shizuka M., Urakami K., Matsubara E., Harigaya Y., Okamoto K., Shoji M. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci. Lett. 267:1999;65-68.
13. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
14. Nitsch R.M., Rebeck G.W., Deng M., Richardson U.I., Tennis M., Schenk D.B., Vigo-Pelfrey C., Lieberburg I., Wurtman R.J., Hyman B.T. Cerebrospinal fluid levels of amyloid β-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann. Neurol. 37:1995;512-518.
15. Nordberg A. The effect of cholinesterase inhibitors studied with brain imaging. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. 2000;237-247 Martin Dunitz Ltd, London.
16. Smith G.S., deLeon M., George A.E., Kluger A., Volkow N.D., McRae T., Golomb J., Ferris S.H., Reisberg B., Ciaravino J. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch. Neurol. 49:1992;1142-1150.
17. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D., Apolipoprotein E. high-avidity binding to B-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. 90:1993;1977-1981.
18. Strittmatter W.J., Weisgraber K.H., Goedert M., Saunders A.M., Huang D., Corder E.H., Dong L.M., Jakes R., Alberts M.J., Gilbert J.R. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125:1994;163-171.
19. Tapiola T., Lehtovirta M., Ramberg J., Helisalmi S., Linnaranta K., Riekkinen P.S., Soininen H. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 50:1998;169-174.
20. Tapiola T., Pirttila T., Mikkonen M., Mehta P.D., Alafuzoff I., Koivisto K., Soininen H. Three years follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 280:2000;119-122.
21. Vanderstichele H., Blennow K., D'Heuvaert N., Buyse M.-A., Wallin A., Andreasen A., Seubert P., van de Voorde A., Vanmechelen E. Development of a specific diagnostic test for measurement of β-amyloid (1-42) in CSF. Fisher A., Hanin I., Yoshida M., et al. Progress in Alzheimer and Parkinson Diseases. 1998;773-778 Plenum Press, New York.